A global scientific strategy to cure hepatitis B
Tóm tắt
Từ khóa
Tài liệu tham khảo
Stanaway, 2016, The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013, Lancet, 388, 1081, 10.1016/S0140-6736(16)30579-7
Chisari, 1995, Hepatitis B virus immunopathogenesis, Annu Rev Immunol, 13, 29, 10.1146/annurev.iy.13.040195.000333
Grossi, 2017, Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs), Liver Int, 37, 45, 10.1111/liv.13291
O'Hara, 2017, Hepatitis B virus infection as a neglected tropical disease, PLoS Negl Trop Dis, 11, e0005842, 10.1371/journal.pntd.0005842
Revill, 2016, Global strategies are required to cure and eliminate HBV infection, Nat Rev Gastroenterol Hepatol, 13, 239, 10.1038/nrgastro.2016.7
Yan, 2012, Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus, eLife, 1, e00049, 10.7554/eLife.00049
Nassal, 2015, HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B, Gut, 64, 1972, 10.1136/gutjnl-2015-309809
Newbold, 1995, The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes, J Virol, 69, 3350, 10.1128/JVI.69.6.3350-3357.1995
Bock, 2001, Structural organization of the hepatitis B virus minichromosome, J Mol Biol, 307, 183, 10.1006/jmbi.2000.4481
Messageot, 2003, Proteolytic processing of the hepatitis B virus e antigen precursor. Cleavage at two furin consensus sequences, J Biol Chem, 278, 891, 10.1074/jbc.M207634200
2017, EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection, J Hepatol, 67, 370, 10.1016/j.jhep.2017.03.021
Michalak, 1994, Hepatitis B virus persistence after recovery from acute viral hepatitis, J Clin Invest, 93, 230, 10.1172/JCI116950
Rehermann, 1996, The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response, Nat Med, 2, 1104, 10.1038/nm1096-1104
Werle-Lapostolle, 2004, Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy, Gastroenterology, 126, 1750, 10.1053/j.gastro.2004.03.018
Seetharam, 2014, Immunosuppression in patients with chronic hepatitis B, Curr Hepatol Rep, 13, 235, 10.1007/s11901-014-0238-2
2018, Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study, Lancet Gastroenterol Hepatol, 3, 383, 10.1016/S2468-1253(18)30056-6
2016
Lazarus, 2018, The hepatitis B epidemic and the urgent need for cure preparedness, Nat Rev Gastroenterol Hepatol, 15, 517, 10.1038/s41575-018-0041-6
Nayagam, 2016, Requirements for global elimination of hepatitis B: a modelling study, Lancet Infect Dis, 16, 1399, 10.1016/S1473-3099(16)30204-3
Zoulim, 2009, Hepatitis B virus resistance to nucleos(t)ide analogues, Gastroenterology, 137, 1593, 10.1053/j.gastro.2009.08.063
Belloni, 2012, IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome, J Clin Invest, 122, 529, 10.1172/JCI58847
Wieland, 2005, Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids, Proc Natl Acad Sci USA, 102, 9913, 10.1073/pnas.0504273102
Gill, 2016, Interferon alpha induces sustained changes in NK cell responsiveness to hepatitis B viral load suppression in vivo, PLoS Pathog, 12, e1005788, 10.1371/journal.ppat.1005788
Maini, 2016, The role of innate immunity in the immunopathology and treatment of HBV infection, J Hepatol, 64, S60, 10.1016/j.jhep.2016.01.028
Maini, 2013, NK cells: a double-edged sword in chronic hepatitis B virus infection, Front Immunol, 4, 57, 10.3389/fimmu.2013.00057
Kramvis, 2014, Genotypes and genetic variability of hepatitis B virus, Intervirology, 57, 141, 10.1159/000360947
Chen, 2007, Long-term outcomes in hepatitis B: the REVEAL-HBV study, Clin Liver Dis, 11, 797, 10.1016/j.cld.2007.08.005
Yuen, 2008, HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma, Gastroenterology, 135, 1192, 10.1053/j.gastro.2008.07.008
Lok, 2017, Hepatitis B cure: from discovery to regulatory approval, Hepatology, 66, 1296, 10.1002/hep.29323
Zeisel, 2015, Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure, Gut, 64, 1314, 10.1136/gutjnl-2014-308943
Thimme, 2003, CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection, J Virol, 77, 68, 10.1128/JVI.77.1.68-76.2003
Guidotti, 1999, Viral clearance without destruction of infected cells during acute HBV infection, Science, 284, 825, 10.1126/science.284.5415.825
Rehermann, 2003, Immune responses in hepatitis B virus infection, Semin Liver Dis, 23, 21, 10.1055/s-2003-37586
Hosaka, 2013, Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection, Hepatology, 58, 98, 10.1002/hep.26180
Papatheodoridis, 2017, The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B, Hepatology, 66, 1444, 10.1002/hep.29320
Strick-Marchand, 2015, A novel mouse model for stable engraftment of a human immune system and human hepatocytes, PLoS One, 10, e0119820, 10.1371/journal.pone.0119820
Kah, 2017, Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection, J Clin Invest, 127, 3177, 10.1172/JCI93024
Klumpp, 2018, Efficacy of NVR 3-778, alone and in combination with pegylated interferon, vs entecavir in uPA/SCID mice with humanized livers and HBV infection, Gastroenterology, 154, 652, 10.1053/j.gastro.2017.10.017
Lucifora, 2014, Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA, Science, 343, 1221, 10.1126/science.1243462
Wu, 2018, Establishment of cre-mediated HBV recombinant cccDNA (rcccDNA) cell line for cccDNA biology and antiviral screening assays, Antiviral Res, 152, 45, 10.1016/j.antiviral.2018.02.007
Xia, 2016, Interferon-gamma and tumor necrosis factor-alpha produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis, Gastroenterology, 150, 194, 10.1053/j.gastro.2015.09.026
Chisari, 2014, Comment on “Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA”, Science, 344, 1237, 10.1126/science.1254082
Xia, 2014, Response to Comment on “Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA”, Science, 344, 1237, 10.1126/science.1254083
Seeger, 2016, Complete spectrum of CRISPR/Cas9-induced mutations on HBV cccDNA, Mol Ther, 24, 1258, 10.1038/mt.2016.94
Bloom, 2017, A T7 endonuclease I assay to detect talen-mediated targeted mutation of HBV cccDNA, Methods Mol Biol, 1540, 85, 10.1007/978-1-4939-6700-1_8
Yang, 2014, Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance, Emerg Microbes Infect, 3, e64, 10.1038/emi.2014.64
Belloni, 2009, Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function, Proc Natl Acad Sci USA, 106, 19975, 10.1073/pnas.0908365106
Levrero, 2009, Control of cccDNA function in hepatitis B virus infection, J Hepatol, 51, 581, 10.1016/j.jhep.2009.05.022
Lucifora, 2011, Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection, J Hepatol, 55, 996, 10.1016/j.jhep.2011.02.015
Pollicino, 2006, Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones, Gastroenterology, 130, 823, 10.1053/j.gastro.2006.01.001
Guo, 2011, HBc binds to the CpG islands of HBV cccDNA and promotes an epigenetic permissive state, Epigenetics, 6, 720, 10.4161/epi.6.6.15815
Decorsiere, 2016, Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor, Nature, 531, 386, 10.1038/nature17170
Livingston, 2017, Identifying and characterizing interplay between hepatitis B virus X protein and Smc5/6, Viruses, 9, E69, 10.3390/v9040069
Murphy, 2016, Hepatitis B virus X protein promotes degradation of SMC5/6 to enhance HBV replication, Cell Rep, 16, 2846, 10.1016/j.celrep.2016.08.026
Wooddell, 2017, RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg, Sci Transl Med, 9, 10.1126/scitranslmed.aan0241
Maepa, 2017, Sustained inhibition of HBV replication in vivo after systemic injection of AAVs encoding artificial antiviral primary microRNAs, Mol Ther Nucleic Acids, 7, 190, 10.1016/j.omtn.2017.04.007
Zhang, 2016, In situ analysis of intrahepatic virological events in chronic hepatitis B virus infection, J Clin Invest, 126, 1079, 10.1172/JCI83339
Li, 2018, Distribution of hepatitis B virus nuclear DNA, J Virol, 92, e01391
Cai, 2016, Establishment of an inducible HBV stable cell line that expresses cccDNA-dependent epitope-tagged HBeAg for screening of cccDNA modulators, Antiviral Res, 132, 26, 10.1016/j.antiviral.2016.05.005
Guo, 2015, Metabolism and function of hepatitis B virus cccDNA: implications for the development of cccDNA-targeting antiviral therapeutics, Antiviral Res, 122, 91, 10.1016/j.antiviral.2015.08.005
Li, 2016, Minicircle HBV cccDNA with a Gaussia luciferase reporter for investigating HBV cccDNA biology and developing cccDNA-targeting drugs, Sci Rep, 6, 36483, 10.1038/srep36483
Thomas, 2016, Experimental models of hepatitis B and C- new insights and progress, Nat Rev Gastroenterol Hepatol, 13, 362, 10.1038/nrgastro.2016.37
Xia, 2017, Human stem cell-derived hepatocytes as a model for hepatitis B virus infection, spreading and virus-host interactions, J Hepatol, 66, 494, 10.1016/j.jhep.2016.10.009
Kaneko, 2016, Human induced pluripotent stem cell-derived hepatic cell lines as a new model for host interaction with hepatitis B virus, Sci Rep, 6, 29358, 10.1038/srep29358
Sakurai, 2017, Human induced-pluripotent stem cell-derived hepatocyte-like cells as an in vitro model of human hepatitis B virus infection, Sci Rep, 7, 45698, 10.1038/srep45698
Ortega-Prieto, 2018, 3D microfluidic liver cultures as a physiological preclinical tool for hepatitis B virus infection, Nat Commun, 9, 682, 10.1038/s41467-018-02969-8
Allweiss, 2018, Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo, Gut, 67, 542, 10.1136/gutjnl-2016-312162
Dusseaux, 2017, Viral load affects the immune response to HBV in mice with humanized immune system and liver, Gastroenterology, 153, 1647, 10.1053/j.gastro.2017.08.034
Cui, 2015, Hepatitis B virus covalently closed circular DNA formation in immortalized mouse hepatocytes associated with nucleocapsid destabilization, J Virol, 89, 9021, 10.1128/JVI.01261-15
Glebe, 2003, Pre-s1 antigen-dependent infection of Tupaia hepatocyte cultures with human hepatitis B virus, J Virol, 77, 9511, 10.1128/JVI.77.17.9511-9521.2003
Walter, 1996, Hepatitis B virus infection of tupaia hepatocytes in vitro and in vivo, Hepatology, 24, 1
Burwitz, 2017, Hepatocytic expression of human sodium-taurocholate cotransporting polypeptide enables hepatitis B virus infection of macaques, Nat Commun, 8, 2146, 10.1038/s41467-017-01953-y
Clements, 2011, A simian immunodeficiency virus macaque model of highly active antiretroviral treatment: viral latency in the periphery and the central nervous system, Curr Opin HIV AIDS, 6, 37, 10.1097/COH.0b013e3283412413
Hu, 2017, Complete and incomplete hepatitis B virus particles: formation, function and application, Viruses, 9, 10.3390/v9030056
Giersch, 2017, Serum HBV pgRNA as a clinical marker for cccDNA activity, J Hepatol, 66, 460, 10.1016/j.jhep.2016.09.028
van Bommel, 2015, Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors, Hepatology, 61, 66, 10.1002/hep.27381
Wang, 2016, Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound, J Hepatol, 65, 700, 10.1016/j.jhep.2016.05.029
Asabe, 2009, The size of the viral inoculum contributes to the outcome of hepatitis B virus infection, J Virol, 83, 9652, 10.1128/JVI.00867-09
Ebert, 2011, 5′ triphosphorylated small interfering RNAs control replication of hepatitis B virus and induce an interferon response in human liver cells and mice, Gastroenterology, 141, 696, 10.1053/j.gastro.2011.05.001
Isogawa, 2005, Toll-like receptor signaling inhibits hepatitis B virus replication in vivo, J Virol, 79, 7269, 10.1128/JVI.79.11.7269-7272.2005
Janssen, 2018, Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B, J Hepatol, 68, 431, 10.1016/j.jhep.2017.10.027
Suresh, 2017, Antiviral efficacy and host immune response induction during sequential treatment with SB 9200 followed by entecavir in woodchucks, PLoS One, 12, e0169631, 10.1371/journal.pone.0169631
Bengsch, 2014, Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation, J Hepatol, 61, 1212, 10.1016/j.jhep.2014.07.005
Boni, 2007, Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection, J Virol, 81, 4215, 10.1128/JVI.02844-06
Fisicaro, 2010, Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B, Gastroenterology, 138, 682, 10.1053/j.gastro.2009.09.052
Nebbia, 2012, Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection, PLoS One, 7, e47648, 10.1371/journal.pone.0047648
Schurich, 2011, Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-prone CD8 T cells in persistent hepatitis B virus infection, Hepatology, 53, 1494, 10.1002/hep.24249
Isogawa, 2013, CD40 activation rescues antiviral CD8(+) T cells from PD-1-mediated exhaustion, PLoS Pathog, 9, e1003490, 10.1371/journal.ppat.1003490
Maier, 2007, PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver, J Immunol, 178, 2714, 10.4049/jimmunol.178.5.2714
Schurich, 2013, The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells, PLoS Pathog, 9, e1003208, 10.1371/journal.ppat.1003208
Gehring, 2017, New treatments to reach functional cure: rationale and challenges for emerging immune-based therapies, Best Pract Res Clin Gastroenterol, 31, 337, 10.1016/j.bpg.2017.05.004
Pallett, 2017, IL-2(high) tissue-resident T cells in the human liver: sentinels for hepatotropic infection, J Exp Med, 214, 1567, 10.1084/jem.20162115
Stegmann, 2016, CXCR6 marks a novel subset of T-bet(lo)Eomes(hi) natural killer cells residing in human liver, Sci Rep, 6, 26157, 10.1038/srep26157
Boeijen, 2017, Hepatitis B virus infection and the immune response: the big questions, Best Pract Res Clin Gastroenterol, 31, 265, 10.1016/j.bpg.2017.05.003
Rehermann, 1996, Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients, J Virol, 70, 7092, 10.1128/JVI.70.10.7092-7102.1996
Knolle, 2014, Hepatic immune regulation and its involvement in viral hepatitis infection, Gastroenterology, 146, 1193, 10.1053/j.gastro.2013.12.036
Das, 2008, Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection, J Exp Med, 205, 2111, 10.1084/jem.20072076
Fisicaro, 2017, Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B, Nat Med, 23, 327, 10.1038/nm.4275
Urbani, 2005, Acute phase HBV-specific T cell responses associated with HBV persistence after HBV/HCV coinfection, Hepatology, 41, 826, 10.1002/hep.20614
Das, 2012, IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection, J Immunol, 189, 3925, 10.4049/jimmunol.1103139
Xu, 2006, Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B, J Immunol, 177, 739, 10.4049/jimmunol.177.1.739
Pallett, 2015, Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells, Nat Med, 21, 591, 10.1038/nm.3856
Peppa, 2013, Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion, J Exp Med, 210, 99, 10.1084/jem.20121172
Bertoletti, 2016, Adaptive immunity in HBV infection, J Hepatol, 64, S71, 10.1016/j.jhep.2016.01.026
Vanwolleghem, 2015, Re-evaluation of hepatitis B virus clinical phases by systems biology identifies unappreciated roles for the innate immune response and B cells, Hepatology, 62, 87, 10.1002/hep.27805
Paul, 2017, Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: a meta-analysis, Hepatology, 66, 379, 10.1002/hep.29082
Perrillo, 2015, American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy, Gastroenterology, 148, 221, 10.1053/j.gastro.2014.10.038
Mason, 2016, HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant, Gastroenterology, 151, 986, 10.1053/j.gastro.2016.07.012
Tjwa, 2016, Similar frequencies, phenotype and activation status of intrahepatic NK cells in chronic HBV patients after long-term treatment with tenofovir disoproxil fumarate (TDF), Antiviral Res, 132, 70, 10.1016/j.antiviral.2016.05.016
Liu, 2014, Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection, PLoS Pathog, 10, e1003856, 10.1371/journal.ppat.1003856
Bohne, 2008, T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes, Gastroenterology, 134, 239, 10.1053/j.gastro.2007.11.002
Gehring, 2011, Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines, J Hepatol, 55, 103, 10.1016/j.jhep.2010.10.025
Koh, 2013, A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus, Mol Ther Nucleic Acids, 2, e114, 10.1038/mtna.2013.43
Krebs, 2013, T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice, Gastroenterology, 145, 456, 10.1053/j.gastro.2013.04.047
Qasim, 2015, Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient, J Hepatol, 62, 486, 10.1016/j.jhep.2014.10.001
Tu, 2018, Hepatitis B virus DNA integration occurs early in the viral life cycle in an in vitro infection model via NTCP-dependent uptake of enveloped virus particles, J Virol, 92, 10.1128/JVI.02007-17
Zhao, 2016, Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma, Nat Commun, 7, 12992, 10.1038/ncomms12992
Alter, 2018, A research agenda for curing chronic hepatitis B virus infection, Hepatology, 67, 1127, 10.1002/hep.29509